BIIB Quote, Financials, Valuation and Earnings

Amgen has a net margin of 9.89% compared to Biogen's net margin of 21.23%. Biogen's return on equity of 9.11% beat Amgen's return on equity of 97.08%.

Biogen has a consensus price target of $172.51, signalling upside risk potential of 34.29%. On the other hand Amgen has an analysts' consensus of $313.56 which suggests that it could grow by 4.86%. Given that Biogen has higher upside potential than Amgen, analysts believe Biogen is more attractive than Amgen.

Biogen has a beta of 0.141, which suggesting that the stock is 85.86% less volatile than S&P 500. In comparison Amgen has a beta of 0.491, suggesting its less volatile than the S&P 500 by 50.876%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.1% to investors and pays a quarterly dividend of $2.38 per share. Biogen pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

Biogen quarterly revenues are $2.4B, which are smaller than Amgen quarterly revenues of $8.1B. Biogen's net income of $240.5M is lower than Amgen's net income of $1.7B. Notably, Biogen's price-to-earnings ratio is 12.68x while Amgen's PE ratio is 27.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.91x versus 4.74x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of 9.89% compared to Biogen's net margin of -111.65%. Biogen's return on equity of 9.11% beat Ionis Pharmaceuticals's return on equity of -100.15%.

Biogen has a consensus price target of $172.51, signalling upside risk potential of 34.29%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $58.38 which suggests that it could grow by 36.49%. Given that Ionis Pharmaceuticals has higher upside potential than Biogen, analysts believe Ionis Pharmaceuticals is more attractive than Biogen.

Biogen has a beta of 0.141, which suggesting that the stock is 85.86% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.230, suggesting its less volatile than the S&P 500 by 77.021%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.4B, which are larger than Ionis Pharmaceuticals quarterly revenues of $131.6M. Biogen's net income of $240.5M is higher than Ionis Pharmaceuticals's net income of -$146.9M. Notably, Biogen's price-to-earnings ratio is 12.68x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.91x versus 9.11x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 9.89% compared to Biogen's net margin of 21.68%. Biogen's return on equity of 9.11% beat Eli Lilly and's return on equity of 78.25%.

Biogen has a consensus price target of $172.51, signalling upside risk potential of 34.29%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Biogen has higher upside potential than Eli Lilly and, analysts believe Biogen is more attractive than Eli Lilly and.

Biogen has a beta of 0.141, which suggesting that the stock is 85.86% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Biogen pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen quarterly revenues are $2.4B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Biogen's net income of $240.5M is lower than Eli Lilly and's net income of $2.8B. Notably, Biogen's price-to-earnings ratio is 12.68x while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.91x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 9.89% compared to Biogen's net margin of -907.48%. Biogen's return on equity of 9.11% beat Moderna's return on equity of -29.23%.

Biogen has a consensus price target of $172.51, signalling upside risk potential of 34.29%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

Biogen has a beta of 0.141, which suggesting that the stock is 85.86% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.4B, which are larger than Moderna quarterly revenues of $107M. Biogen's net income of $240.5M is higher than Moderna's net income of -$971M. Notably, Biogen's price-to-earnings ratio is 12.68x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.91x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.